Anti-inflammatory strategies for ventricular remodeling following St-segment elevation acute myocardial infarction

Journal of the American College of Cardiology

Volumn 63, Issue 16, 2014, Pages 1593-1603

  Seropian, Ignacio M ^a   Toldo, Stefano ^b,c   Van Tassell, Benjamin W ^b,c   Abbate, Antonio ^b,c  

^a FLENI   (Argentina)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

acute myocardial infarction; inflammation; ventricular remodeling

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ALPHA 1 ANTITRYPSIN; C REACTIVE PROTEIN; COBROTOXIN; COMPLEMENT COMPONENT C1; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C5A; CYTOKINE; DEXAMETHASONE; DOXYCYCLINE; ETANERCEPT; GLUCOCORTICOID; HYDROCORTISONE; INCLACUMAB; INFLIXIMAB; INTEGRIN; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; MELOXICAM; MEPREDNISONE; NONSTEROID ANTIINFLAMMATORY AGENT; PEXELIZUMAB; PG 116800; PLACEBO; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; IMMUNOGLOBULIN; METALLOPROTEINASE; PADGEM PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; TG 100 115;

ACUTE HEART INFARCTION; ANGINA PECTORIS; ANGIOPLASTY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; COMPLEMENT SYSTEM; DRUG TOLERABILITY; HEALING IMPAIRMENT; HEART FAILURE; HEART INFARCTION; HEART MUSCLE INJURY; HEART RUPTURE; HEART VENTRICLE REMODELING; HUMAN; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; NONHUMAN; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REPERFUSION INJURY; RISK ASSESSMENT; RISK FACTOR; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; ANTERIOR MYOCARDIAL INFARCTION; CARDITIS; COMPLEMENT ACTIVATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; TREATMENT OUTCOME;

ACUTE MYOCARDIAL INFARCTION; INFLAMMATION; VENTRICULAR REMODELING;

ANIMALS; ANTI-INFLAMMATORY AGENTS; C-REACTIVE PROTEIN; CYTOKINES; HUMANS; INFLAMMATION; INTEGRINS; MYOCARDIAL INFARCTION; VENTRICULAR REMODELING;

EID: 84899010755     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2014.01.014     Document Type: Review

References (127)

1. National Heart Lung and Blood Institute Morbidity and Mortality: 2012 Chart Book on Cardiovascular and Lung Diseases 2012 NIH Bethesda, MD
2. Z.J. Eapen, W.H.W. Tang, and G.M. Felker et al. Defining heart failure end points in ST-segment elevation myocardial infarction trials: integrating past experiences to chart a path forward Circ Cardiovasc Qual Outcomes 5 2012 594 600
3. J.M. Pfeffer, M.A. Pfeffer, and E. Braunwald Influence of chronic captopril therapy on the infarcted left ventricle of the rat Circ Res 57 1985 84 95
4. J.N. Cohn, R. Ferrari, and N. Sharpe Cardiac remodeling - concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling J Am Coll Cardiol 35 2000 569 582
5. D.G. Kramer, T.A. Trikalinos, D.M. Kent, G.V. Antonopoulos, M.A. Konstam, and J.E. Udelson Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach J Am Coll Cardiol 56 2010 392 406
6. N.G. Frangogiannis The immune system and the remodeling infarcted heart: cell biological insights and therapeutic opportunities J Cardiovasc Pharmacol 63 2014 185 195
7. A. Abbate, G.G. Biondi-Zoccai, and A. Baldi Pathophysiologic role of myocardial apoptosis in post-infarction left ventricular remodeling J Cell Physiol 193 2002 145 153
8. X. Yan, A. Anzai, and Y. Katsumata et al. Temporal dynamics of cardiac immune cell accumulation following acute myocardial infarction J Mol Cell Cardiol 62 2013 24 35
9. M. Nahrendorf, and F.K. Swirski Monocyte and macrophage heterogeneity in the heart Circ Res 112 2013 1624 1633
10. Y.-H. Liao, and X. Cheng Autoimmunity in myocardial infarction Int J Cardiol 112 2006 21 26
11. E. Mezzaroma, S. Toldo, and D. Farkas et al. The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouse Proc Natl Acad Sci U S A 108 2011 19725 19730
12. B.W. Van Tassell, S. Toldo, E. Mezzaroma, and A. Abbate Targeting interleukin-1 in heart disease Circulation 128 2013 1910 1923
13. D. Hausenloy, and D. Yellon Myocardial ischemia-reperfusion injury: a neglected therapeutic target J Clin Invest 123 2013 92 100
14. T. Rhen, and J.A. Cidlowski Antiinflammatory action of glucocorticoids-new mechanisms for old drugs N Engl J Med 353 2005 1711 1723
15. P. Libby, P.R. Maroko, C.M. Bloor, B.E. Sobel, and E. Braunwald Reduction of experimental myocardial infarct size by corticosteroid administration J Clin Invest 52 1973 599 607
16. T.N. Masters, N.B. Harbold Jr., and D.G. Hall et al. Beneficial metabolic effects of methylprednisolone sodium succinate in acute myocardial ischemia Am J Cardiol 37 1976 557 563
17. R.A. Kloner, M.C. Fishbein, H. Lew, P.R. Maroko, and E. Braunwald Mummification of the infarcted myocardium by high dose corticosteroids Circulation 57 1978 56 63
18. H. Hammerman, R.A. Kloner, S. Hale, F.J. Schoen, and E. Braunwald Dose-dependent effects of short-term methylprednisolone on myocardial infarct extent, scar formation, and ventricular function Circulation 68 1983 446 452
19. G.R. Giugliano, R.P. Giugliano, C.M. Gibson, and R.E. Kuntz Meta-analysis of corticosteroid treatment in acute myocardial infarction Am J Cardiol 91 2003 1055 1059
20. American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions, P.T. O'Gara, F.G. Kushner, and D.D. Ascheim et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 61 2013 e78 e146
21. P.G. Steg, S.K. James, and D. Atar et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC) Eur Heart J 33 2012 2569 2619
22. E.M. Antman, D. DeMets, and J. Loscalzo Cyclooxygenase inhibition and cardiovascular risk Circulation 112 2005 759 770
23. A. Lefer, and E. Polansky Beneficial effects of ibuprofen in acute myocardial ischemia Cardiology 64 1979 265 279
24. J. Romson, and L. Bush Cardioprotective effects of ibuprofen in experimental regional and global myocardial ischemia J Cardiovasc Pharmacol 4 1982 187 196
25. B.I. Jugdutt Delayed effects of early infarct-limiting therapies on healing after myocardial infarction Circulation 72 1985 907 914
26. H. Hammerman, R.A. Kloner, F.J. Schoen, E.J. Brown, S. Hale, and E. Braunwald Indomethacin-induced scar thinning after experimental myocardial infarction Circulation 67 1983 1290 1295
27. H. Hammerman, F.J. Schoen, E. Braunwald, and R.A. Kloner Drug-induced expansion of infarct: morphologic and functional correlations Circulation 69 1984 611 617
28. D. Chambers, and D. Yellon Effects of flurbiprofen in altering the size of myocardial infarcts in dogs: reduction or delay? Am J Cardiol 51 1983 187 196
29. M.A. Pfeffer, and E. Braunwald Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications Circulation 81 1990 1161 1172
30. C.M. Gibson, Y.B. Pride, and P.E. Aylward et al. Association of non-steroidal anti-inflammatory drugs with outcomes in patients with ST-segment elevation myocardial infarction treated with fibrinolytic therapy: an ExTRACT-TIMI 25 analysis J Thromb Thrombolysis 27 2009 11 17
31. H. Silverman, and M. Pfeifer Relation between use of antiinflammatory agents and left ventricular free wall rupture during acute myocardial infarction Am J Cardiol 59 1987 363 364
32. B. Jugdutt, and C. Basualdo Myocardial infarct expansion during indomethacin or ibuprofen therapy for symptomatic post infarction pericarditis. Influence of other pharmacologic agents during Can J Cardiol 5 1989 211 221
33. G.H. Gislason, S. Jacobsen, and J.N. Rasmussen et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction Circulation 113 2006 2906 2913
34. P.M. Kearney, C. Baigent, J. Godwin, H. Halls, J.R. Emberson, and C. Patrono Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials BMJ 332 2006 1302 1308
35. T. Saito, I.W. Rodger, F. Hu, H. Shennib, and A. Giaid Inhibition of cyclooxygenase-2 improves cardiac function in myocardial infarction Biochem Biophys Res Commun 273 2000 772 775
36. T. Saito, I. Rodger, and H. Shennib Cyclooxygenase-2 (COX-2) in acute myocardial infarction: cellular expression and use of selective COX-2 inhibitor Can J Physiol Pharmacol 81 2003 114 119
37. L. Timmers, J.P.G. Sluijter, and C.W.J. Verlaan et al. Cyclooxygenase-2 inhibition increases mortality, enhances left ventricular remodeling, and impairs systolic function after myocardial infarction in the pig Circulation 115 2007 326 332
38. S. Straino, F.N. Salloum, and A. Baldi et al. Protective effects of parecoxib, a cyclo-oxygenase-2 inhibitor, in postinfarction remodeling in the rat J Cardiovasc Pharmacol 50 2007 571 577
39. F.N. Salloum, N.N. Hoke, and I.M. Seropian et al. Parecoxib inhibits apoptosis in acute myocardial infarction due to permanent coronary ligation but not due to ischemia-reperfusion J Cardiovasc Pharmacol 53 2009 495 498
40. R. Altman Efficacy assessment of meloxicam, a preferential cyclooxygenase-2 inhibitor, in acute coronary syndromes without st-segment elevation: the Nonsteroidal Anti-Inflammatory Drugs in Unstable Angina Treatment-2 (NUT-2) Pilot Study Circulation 106 2002 191 195
41. L. Timmers, G. Pasterkamp, V.C. de Hoog, F. Arslan, Y. Appelman, and D.P.V. de Kleijn The innate immune response in reperfused myocardium Cardiovasc Res 94 2012 276 283
42. A. Palazzo, and S. Jones Myocardial ischemia-reperfusion injury in CD18-and ICAM-1-deficient mice Am J Physiol 275 1998 2300 2307
43. S. Sharar, and D. Mihelcic Ischemia reperfusion injury in the rabbit ear is reduced by both immediate and delayed CD18 leukocyte adherence blockade J Immunol 18 1994 2 6
44. P. Simpson, and R. Todd Reduction of experimental canine myocardial reperfusion injury by a monoclonal antibody (anti-Mo1, anti-CD11b) that inhibits leukocyte adhesion J Clin Invest 81 1988 624 629
45. M. Tanaka, S.E. Brooks, and V.J. Richard et al. Effect of anti-CD18 antibody on myocardial neutrophil accumulation and infarct size after ischemia and reperfusion in dogs Circulation 87 1993 526 535
46. M. Arai, D.J. Lefer, T. So, A. DiPaula, T. Aversano, and L.C. Becker An anti-CD18 antibody limits infarct size and preserves left ventricular function in dogs with ischemia and 48-hour reperfusion J Am Coll Cardiol 27 1996 1278 1285
47. T. Aversano, W. Zhou, M. Nedelman, M. Nakada, and H. Weisman A chimeric IgG4 monoclonal antibody directed against CD18 reduces infarct size in a primate model of myocardial ischemia and reperfusion J Am Coll Cardiol 25 1995 781 788
48. K.W. Baran, M. Nguyen, and G.R. McKendall et al. Double-blind, randomized trial of an anti-CD18 antibody in conjunction with recombinant tissue plasminogen activator for acute myocardial infarction: Limitation of Myocardial Infarction Following Thrombolysis in Acute Myocardial Infarction (LIMIT AMI) study Circulation 104 2001 2778 2783
49. D.P. Faxon, R.J. Gibbons, N.A. Chronos, P.A. Gurbel, F. Sheehan HALT-MI Investigators The effect of blockade of the CD11/CD18 integrin receptor on infarct size in patients with acute myocardial infarction treated with direct angioplasty: the results of the HALT-MI study J Am Coll Cardiol 40 2002 1199 1204
50. A. Blann The adhesion molecule P-selectin and cardiovascular disease Eur Heart J 24 2003 2166 2179
51. K. Wang, X. Zhou, and Z. Zhou et al. Recombinant soluble P-selectin glycoprotein ligand-Ig (rPSGL-Ig) attenuates infarct size and myeloperoxidase activity in a canine model of ischemia-reperfusion Thromb Haemost 88 2002 149 154
52. J.-C. Tardif, J.-F. Tanguay, and S.S. Wright et al. Effects of the P-selectin antagonist inclacumab on myocardial damage after percutaneous coronary intervention for non-ST-segment elevation myocardial infarction: results of the SELECT-ACS trial J Am Coll Cardiol 61 2013 2048 2055
53. F. Alfonso, and D.J. Angiolillo Targeting p-selectin during coronary interventions: the elusive link between inflammation and platelets to prevent myocardial damage J Am Coll Cardiol 61 2013 2056 2059
54. S. Mackrides Therapeutic inhibition of the complement system Pharmacol Rev 50 1998 59 87
55. M. Buerke, T. Murohara, and A. Lefer Cardioprotective effects of a C1 esterase inhibitor in myocardial ischemia and reperfusion Circulation 91 1995 393 402
56. M. Buerke, D. Prüfer, M. Dahm, H. Oelert, J. Meyer, and H. Darius Blocking of classical complement pathway inhibits endothelial adhesion molecule expression and preserves ischemic myocardium from reperfusion injury J Pharmacol Exp Ther 286 1998 429 438
57. T. Murohara, and J. Guo Cardioprotective effects of selective inhibition of the two complement activation pathways in myocardial ischemia and reperfusion injury Methods Find Exp Clin Pharmacol 17 1995 499 507
58. J. Fu, G. Lin, and Z. Wu et al. Anti-apoptotic role for C1 inhibitor in ischemia/reperfusion-induced myocardial cell injury Biochem Biophys Res Commun 349 2006 504 512
59. G. Horstick, A. Heimann, O. Go, G. Hafner, and O. Berg Intracoronary application of C1 esterase inhibitor improves cardiac function and reduces myocardial necrosis in an experimental model of ischemia and reperfusion Circulation 95 1997 701 708
60. M. Buerke, H. Schwertz, W. Seitz, J. Meyer, and H. Darius Novel small molecule inhibitor of C1s exerts cardioprotective effects in ischemia-reperfusion injury in rabbits J Immunol 167 2001 5375 5380
61. G. Horstick, O. Berg, and A. Heimann et al. Application of C1-esterase inhibitor during reperfusion of ischemic myocardium: dose-related beneficial versus detrimental effects Circulation 104 2001 3125 3131
62. C. De Zwaan Continuous 48-h C1-inhibitor treatment, following reperfusion therapy, in patients with acute myocardial infarction Eur Heart J 23 2002 1670 1677
63. P.R. Maroko, C.B. Carpenter, and M. Chiariello et al. Reduction by cobra venom factor of myocardial necrosis after coronary artery occlusion J Clin Invest 61 1978 661 670
64. W.B. Gorsuch, B.J. Guikema, D.C. Fritzinger, C.-W. Vogel, and G.L. Stahl Humanized cobra venom factor decreases myocardial ischemia-reperfusion injury Mol Immunol 47 2009 506 510
65. A.P. Vakeva, A. Agah, S.A. Rollins, L.A. Matis, L. Li, and G.L. Stahl Myocardial infarction and apoptosis after myocardial ischemia and reperfusion: role of the terminal complement components and inhibition by anti-C5 therapy Circulation 97 1998 2259 2267
66. K.W. Mahaffey, C.B. Granger, and J.C. Nicolau et al. Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial Circulation 108 2003 1176 1183
67. C.B. Granger, K.W. Mahaffey, and W.D. Weaver et al. Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial Circulation 108 2003 1184 1190
68. P. Armstrong, C. Granger, and P. Adams et al. Pexelizumab for Acute ST-Elevation Myocardial Infarction in Patients Undergoing. The APEX AMI Investigators JAMA 297 2007 43 51
69. C.A. Dinarello Interleukin-1 in the pathogenesis and treatment of inflammatory diseases Blood 117 2011 3720 3732
70. M. Bujak, and N.G. Frangogiannis The role of IL-1 in the pathogenesis of heart disease Arch Immunol Ther Exp 57 2009 165 176
71. M. Nian, P. Lee, N. Khaper, and P. Liu Inflammatory cytokines and postmyocardial infarction remodeling Circ Res 94 2004 1543 1553
72. A. Deten, H.C. Volz, W. Briest, and H.-G. Zimmer Cardiac cytokine expression is upregulated in the acute phase after myocardial infarction. Experimental studies in rats Cardiovasc Res 55 2002 329 340
73. R. Schulz, D.L. Panas, M. Olley, and G.D. Lopaschuk The role of nitric oxide in cardiac depression induced by interleukin-1b and tumour necrosis factor-A Br J Pharmacol 114 1995 27 34
74. B.W. Van Tassell, R.A. Arena, and S. Toldo et al. Enhanced interleukin-1 activity contributes to exercise intolerance in patients with systolic heart failure PLoS One 7 2012 e33438
75. B.W. Van Tassell, I.M. Seropian, S. Toldo, E. Mezzaroma, and A. Abbate Interleukin-1β induces a reversible cardiomyopathy in the mouse Inflamm Res 62 2013 637 640
76. A. Abbate, F.N. Salloum, and E. Vecile et al. Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction Circulation 117 2008 2670 2683
77. B.W. Van Tassell, A. Varma, and F.N. Salloum et al. Interleukin-1 trap attenuates cardiac remodeling after experimental acute myocardial infarction in mice J Cardiovasc Pharmacol 55 2010 117 122
78. A. Abbate, B.W. Van Tassell, and I.M. Seropian et al. Interleukin-1beta modulation using a genetically engineered antibody prevents adverse cardiac remodelling following acute myocardial infarction in the mouse Eur J Heart Fail 12 2010 319 322
79. S. Toldo, E. Mezzaroma, and B.W. Van Tassell et al. Interleukin-1β blockade improves cardiac remodelling after myocardial infarction without interrupting the inflammasome in the mouse Exp Physiol 98 2013 734 745
80. B.W. Van Tassell, I.M. Seropian, and S. Toldo et al. Pharmacologic inhibition of myeloid differentiation factor 88 (MyD88) prevents left ventricular dilation and hypertrophy after experimental acute myocardial infarction in the mouse J Cardiovasc Pharmacol 55 2010 385 390
81. M. Bujak, M. Dobaczewski, and K. Chatila et al. Interleukin-1 receptor type I signaling critically regulates infarct healing and cardiac remodeling Am J Pathol 173 2008 57 67
82. A. Abbate, M.C. Kontos, and J.D. Grizzard et al. Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study) Am J Cardiol 105 2010 1371 1377.e1
83. A. Abbate, B.W. Van Tassell, and G. Biondi-Zoccai et al. Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) Pilot Study] Am J Cardiol 111 2013 1394 1400
84. Interleukin-1 Blockade With Canakinumab to Improve Exercise Capacity in Patients With Chronic Systolic Heart Failure and Elevated Hs-CRP. Available at: http://www.clinicaltrials.gov/ct2/show/NCT01900600. Accessed October 15, 2013.
85. H. Gilutz, Y. Siegel, E. Paran, N. Cristal, and M.R. Quastel Alpha 1-antitrypsin in acute myocardial infarction Br Heart J 49 1983 26 29
86. S. Toldo, I.M. Seropian, and E. Mezzaroma et al. Alpha-1 antitrypsin inhibits caspase-1 and protects from acute myocardial ischemia-reperfusion injury J Mol Cell Cardiol 51 2011 244 251
87. Alpha-1 Anti-Trypsin (AAT) Treatment in Acute Myocardial Infarction (VCU-Alpha1RT). Available at: http://www.clinicaltrials.gov/ct2/show/ NCT01936896. Accessed October 15, 2013.
88. I. Guillen, M. Blanes, J.V. Castell, I. Guillfin, and V. Castell Cytokine signaling during myocardial infarction: sequential appearance of IL-1 beta and IL-6 cytokine signaling during myocardial infarction: sequential appearance of ILAp and IL-6 Am J Physiol 269 1995 229 235
89. K. Yamamoto, and S. Rose-John Therapeutic blockade of interleukin-6 in chronic inflammatory disease Clin Pharmacol Ther 91 2012 574 576
90. M. Fuchs, A. Hilfiker, and K. Kaminski Role of interleukin-6 for LV remodeling and survival after experimental myocardial infarction FASEB J 17 2003 2118 2120
91. M. Kobara, K. Noda, and M. Kitamura et al. Antibody against interleukin-6 receptor attenuates left ventricular remodelling after myocardial infarction in mice Cardiovasc Res 87 2010 424 430
92. C. Gabay, P. Emery, and R. van Vollenhoven et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial Lancet 381 2013 1541 1550
93. Effect of the Interleukin-6 Receptor Antagonist Tocilizumab in Non-ST Elevation Myocardial Infarction. Available at: http://www.clinicaltrials.gov/ ct2/show/NCT01491074. Accessed October 15, 2013.
94. Z. Yang, B. Zingarelli, and C. Szabo Crucial role of endogenous interleukin-10 production in myocardial ischemia/reperfusion injury Circulation 101 2000 1019 1026
95. P. Krishnamurthy, J. Rajasingh, E. Lambers, G. Qin, D.W. Losordo, and R. Kishore IL-10 inhibits inflammation and attenuates left ventricular remodeling after myocardial infarction via activation of STAT3 and suppression of HuR Circ Res 104 2009 e9 e18
96. T. Takahashi, and T. Anzai Increased C-reactive protein expression exacerbates left ventricular dysfunction and remodeling after myocardial infarction Am J Physiol Heart Circ Physiol 299 2010 1795 1804
97. A.C. Slagman, C. Bock, and H. Abdel-Aty et al. Specific removal of C-reactive protein by apheresis in a porcine cardiac infarction model Blood Purif 31 2011 9 17
98. N.G. Frangogiannis The mechanistic basis of infarct healing Antioxid Redox Signal 8 2006 1907 1939
99. N.G. Frangogiannis The immune system and cardiac repair Pharmacol Res 58 2008 88 111
100. V. Baud, and M. Karin Signal transduction by tumor necrosis factor and its relatives Trends Cell Biol 11 2001 372 377
101. T. Yokoyama, and L. Vaca Cellular basis for the negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian heart J Clin Invest 92 1993 2303 2312
102. D. Engel, R. Peshock, R.C. Armstong, N. Sivasubramanian, and D.L. Mann Cardiac myocyte apoptosis provokes adverse cardiac remodeling in transgenic mice with targeted TNF overexpression Am J Physiol Hear Circ Physiol 287 2004 H1303 H1311
103. M. Sugano, K. Tsuchida, T. Hata, and N. Makino In vivo transfer of soluble TNF-alpha receptor 1 gene improves cardiac function and reduces infarct size after myocardial infarction in rats FASEB J 18 2004 911 913
104. Y. Monden, T. Kubota, and T. Tsutsumi et al. Soluble TNF receptors prevent apoptosis in infiltrating cells and promote ventricular rupture and remodeling after myocardial infarction Cardiovasc Res 73 2007 794 805
105. M. Sun, F. Dawood, and W.-H. Wen et al. Excessive tumor necrosis factor activation after infarction contributes to susceptibility of myocardial rupture and left ventricular dysfunction Circulation 110 2004 3221 3228
106. Y.T. Sia, T.G. Parker, J.N. Tsoporis, P. Liu, A. Adam, and J.L. Rouleau Long-term effects of carvedilol on left ventricular function, remodeling, and expression of cardiac cytokines after large myocardial infarction in the rat J Cardiovasc Pharmacol 39 2002 73 87
107. Y. Monden, T. Kubota, and T. Inoue et al. Tumor necrosis factor-alpha is toxic via receptor 1 and protective via receptor 2 in a murine model of myocardial infarction Am J Physiol Heart Circ Physiol 293 2007 H743 H753
108. G.J. Padfield, J.N. Din, and E. Koushiappi et al. Cardiovascular effects of tumour necrosis factor α antagonism in patients with acute myocardial infarction: a first in human study Heart 99 2013 1330 1335
109. A.P. Coletta, A.L. Clark, P. Banarjee, and J.G.F. Cleland Clinical trials update: RENEWAL (RENAISSANCE and RECOVER) and ATTACH Eur J Heart Fail 4 2002 559 561
110. E.S. Chung, M. Packer, K.H. Lo, A.A. Fasanmade, and J.T. Willerson Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial Circulation 107 2003 3133 3140
111. S. Matsumura, and S. Iwanaga Targeted deletion or pharmacological inhibition of MMP-2 prevents cardiac rupture after myocardial infarction in mice J Clin Invest 115 2005 599 609
112. A. Ducharme, and S. Frantz Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction J Clin Invest 106 2000 55 62
113. M.P. Hudson, P.W. Armstrong, and W. Ruzyllo et al. Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial J Am Coll Cardiol 48 2006 15 20
114. F.J. Villarreal, M. Griffin, J. Omens, W. Dillmann, J. Nguyen, and J. Covell Early short-term treatment with doxycycline modulates postinfarction left ventricular remodeling Circulation 108 2003 1487 1492
115. G. Cerisano, P. Buonamici, and R. Valenti et al. Early short-term doxycycline therapy in patients with acute myocardial infarction and left ventricular dysfunction to prevent the ominous progression to adverse remodelling: the TIPTOP trial Eur Heart J 35 2014 184 191
116. Safety and Efficacy of Doxycycline in Patients With Non-Ischemic Cardiomyopathy (DOXY-HF). Available at: http://clinicaltrials.gov/ct2/show/ NCT01935622. Accessed October 21, 2013.
117. J.G. Foster, M.D. Blunt, E. Carter, and S.G. Ward Inhibition of PI3K signaling spurs new therapeutic opportunities in inflammatory/autoimmune diseases and hematological malignancies Pharmacol Rev 64 2012 1027 1054
118. A. Tsang, D.J. Hausenloy, M.M. Mocanu, and D.M. Yellon Postconditioning: a form of "modified reperfusion" protects the myocardium by activating the phosphatidylinositol 3-kinase-Akt pathway Circ Res 95 2004 230 232
119. J. Doukas, W. Wrasidlo, G. Noronha, E. Dneprovskaia, J. Hood, and R. Soll Isoform-selective PI3K inhibitors as novel therapeutics for the treatment of acute myocardial infarction Biochem Soc Trans 35 2007 204 206
120. F. Damilano, A. Perino, and E. Hirsch PI3K kinase and scaffold functions in heart Ann N Y Acad Sci 1188 2010 39 45
121. I. Schwab, and F. Nimmerjahn Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat Rev Immunol 13 2013 176 189
122. M. Siragusa, R. Katare, and M. Meloni et al. Involvement of phosphoinositide 3-kinase gamma in angiogenesis and healing of experimental myocardial infarction in mice Circ Res 106 2010 757 768
123. I. Seropian, A. Abbate, and S. Toldo inhibition of phosphoinositide 3-kinase gamma (PI3Kγ) promotes infarct resorption and prevents adverse cardiac remodeling after myocardial infarction in J Cardiovasc Pharmacol 56 2010 651 658
124. I.M. Seropian, S. Toldo, A. Abbate, E. Mezzaroma, and B.W. Van Tassell Effects of PI3Kgamma inhibition using AS-605240 in acute myocardial infarction Circ Res 107 2010 757 768
125. D. Gurantz, A. Yndestad, and B. Halvorsen et al. Etanercept or intravenous immunoglobulin attenuates expression of genes involved in post-myocardial infarction remodeling Cardiovasc Res 67 2005 106 115
126. L. Gullestad, S. Orn, and K. Dickstein et al. Intravenous immunoglobulin does not reduce left ventricular remodeling in patients with myocardial dysfunction during hospitalization after acute myocardial infarction Int J Cardiol 168 2013 212 218
127. P. Libby, P.M. Ridker, and G.K. Hansson Inflammation in atherosclerosis: from pathophysiology to practice J Am Coll Cardiol 54 2009 2129 2138